Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16172113 | 0.67 | MIF (0.40) | ALDH1A1MIF | |
| SCHEMBL818454 | 0.67 | HMGCR (0.40) | ALDH1A1MAPT | |
| SCHEMBL13626225 | 0.66 | MIF (0.30) | MIF | |
| SCHEMBL13612407 | 0.66 | — | — | |
| SCHEMBL13979022 | 0.65 | EPHX1 (0.42) | — | |
| SCHEMBL15867922 | 0.64 | TSHR (0.42) | ALDH1A1 | |
| SCHEMBL14282026 | 0.62 | HMGCR (0.36) | MAPTL3MBTL1 | |
| SCHEMBL14593436 | 0.62 | SMN1; SMN2 (0.37) | ALDH1A1MAPT | |
| SCHEMBL25497716 | 0.60 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL270702 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9950077-B2 | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof | BIOALLIANCE C.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| US-20160015827-A1 | ANTI-FOLATE RECEPTOR ALPHA (FRA) ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | ABGENOMICS HOLDING INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015827-A1 | ANTI-FOLATE RECEPTOR ALPHA (FRA) ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | FOLR1, FOLR2, DHFR | ALDH1A1 885/4885MAPT 3338/4885L3MBTL1 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.